Targeted treatment for chronic lymphocytic leukemia

OncoTargets and Therapy

Volumn 4, Issue , 2011, Pages 169-183

  Masood, Aisha ^a   Sher, Taimur ^b   Paulus, Aneel ^b   Miller, Kena C ^b   Chitta, Kasyapa S ^b   Chanan Khan, Asher ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Akt inhibitors; Bcl 2 inhibitors; CLL; Cyclin d kinase inhibitors; Heat shock protein inhibitors; Immunomodulatory drugs; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BREAKPOINT CLUSTER REGION PROTEIN; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD40 ANTIGEN; CD52 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; DACETUZUMAB; DEATH RECEPTOR; DENILEUKIN DIFTITOX; FLUDARABINE; FOSTAMATINIB; IMMUNOMODULATING AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; LUMILIXIMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PROTEIN KINASE B INHIBITOR; RITUXIMAB; THALIDOMIDE; TRU 016; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; XMAB 5574;

ANEMIA; ANOREXIA; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONJUNCTIVITIS; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPNEA; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERHIDROSIS; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOTENSION; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LUNG EMBOLISM; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PNEUMONIA; PROTEIN TARGETING; REVIEW; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT INDICATION; TUMOR FLARE; TUMOR MICROENVIRONMENT; VIRUS REACTIVATION;

EID: 84858807412     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S7173     Document Type: Review

References (114)

1. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107: 265-276.
2. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-5456.
3. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370: 230-239.
4. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885-891.
5. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23: 4079-4088.
6. Matutes E, Parry-Jones N, Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma. 2004;45:2007-2015.
7. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389.
8. Chiorazzi N FM: Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 2011;117:1781-1791.
9. Gorgun G, Ramsay AG, Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A. 2009;106:6250-6255.
10. Pleyer L, Egle A, Hartmann TN, et al. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009;6:405-418.
11. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005;19:524-530.
12. Danilov AV, Danilova OV, Klein AK, et al. Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med. 2006;6:665-675.
13. Caligris-Cappio F: Role of the microenvironment in chronic lymphocytic leukemia. Br J Hematol. 2003;123:380-388.
14. Chanan-Khan AA, Mavromatis B, Rai KR, et al. A pilot study of genasense (R) (oblimersen sodium, Bcl-2 antisense oligonucleotide), fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2004;104:4827.
15. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009;113:299-305.
16. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10:389-399.
17. Brentjens RJ: Novel approaches to immunotherapy for B-cell malignancies. Curr Hematol Rep. 2005;4:64-72.
18. Ghia P, Granziero L, Chilosi M, et al. Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol. 2002;12:149-155.
19. Glezer E, Ferrajoli A, Reuben JM, et al. Treatment with lenalidomide (Revlimid(R)) upregulates CD40 expression on CLL Cells and increases their sensitivity to CD40-mediated cytotoxicity in vitro. ASH Annual Meeting Abstracts. 2008;112:3168.
20. Herishanu Y, Vire B, Liu D, et al. The role of the microenvironment for CLL proliferation and survival: gene expression profiling of leukemic cells derived from blood, bone marrow and lymph nodes reveals the B-cell receptor and NF {kappa}B as dominant signaling pathways. ASH Annual Meeting Abstracts. 2008;112:356.
21. Osterborg A, Kipps TJ, Mayer J, et al. Ofatumumab (HuMax-CD20), a Novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial. ASH Annual Meeting Abstracts. 2008;112:328.
22. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544-1552.
23. Chanan-Khan AA, Padmanabhan S, Miller KC, et al. In vivo evaluation of immunomodulating effects of lenalidomide (L) on tumor cell microenvironment as a possible underlying mechanism of the antitumor effects observed in patients (pts) with chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2005;106:2975.
24. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005;106:3348-3352.
25. Giannopoulos K, Dmoszynska A, Kowal M, et al. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009;23:1771-1778.
26. Kay NE, Shanafelt TD, Call TG, et al. N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:588-592.
27. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24: 5343-5349.
28. Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010;51:85-88.
29. Musial L, Miller KC, Tonelli A, et al. Low-dose prednisone decreases the severity but not the frequency of lenalidomide associated tumor flare reaction (TFR) in chronic lymphocytic leukemia (CLL) patients. ASH Annual Meeting Abstracts. 2006;108:4987.
30. Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117:2127-2135.
31. Chanan-Khan AA, Czuczman MS, Padmanabhan S, et al. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. ASH Annual Meeting Abstracts. 2007;110:3108.
32. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291-5297.
33. Ferrajoli A, O'Brien SM, Faderl SH, et al. Lenalidomide induces complete and partial responses in patients with relapsed and treatmentrefractory chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2006;108:305.
34. Chen C, Paul H, Xu W, et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2008;112:44.
35. Ferrajoli A, Badoux XC, O'Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2009; 114:206.
36. Chen CI, Paul H, Mariela P, et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2007;110:2042.
37. Badoux X, O'Brien S, Wierda WG, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: initial results of a phase II trial. ASH Annual Meeting Abstracts. 2010;116:2464.
38. Osterborg A. Ofatumumab, a human CD20 monoclonal antibody. Expert Opin Biol Ther. 2010;10:439-449.
39. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98: 1326-1331.
40. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab doseescalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19: 2165-2170.
41. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
42. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
43. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-980.
44. Hallek MFK, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376: 1164-1174.
45. O'Brien S, Osterborg A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010;10(5):361-368.
46. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094-1100.
47. Wierda WG, Kipps TJ, Mayer J, et al. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2010; 116:921.
48. Wierda WG-KT, Mayer J, et al; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabinerefractory chronic lymphocytic leukemia. J Clin Oncol. 2010 28: 1749-1755.
49. Wierda WG, Kipps TJ, Durig J, et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. ASH Annual Meeting Abstracts. 2009;114:207.
50. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009;10:588-596.
51. Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2009;114:884.
52. Milani C, Castillo J: Veltuzumab, an anti-CD20 mAb for the t{stroke}reatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009;11: 200-207.
53. Morschhauser F, Leonard JP, Fayad L, et al. Humanized antiCD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009;27:3346-3353.
54. Goldenberg DM, Rossi EA, Stein R, et al. Properties and structurefunction relationships of veltuzumab (hA20), a humanized antiCD20 monoclonal antibody. Blood. 2009;113:1062-1070.
55. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
56. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15: 1567-1574.
57. Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004;45:2269-2273.
58. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616-5623.
59. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
60. Awan FT, Lapalombella R, Trotta R, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2010;115:1204-1213.
61. Furman RR, Andritsos L, Flinn IW, et al. Phase 1 dose escalation study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and refractory CLL. ASH Annual Meeting Abstracts. 2010;116:56.
62. Andritsos L, Furman RR, Flinn IW, et al. A Phase 1 Trial of TRU-016, An Anti-CD37 small modular immunopharmaceutical (SMIPTM) protein in relapsed and refractory CLL: early promising clinical activity. ASH Annual Meeting Abstracts. 2009;114:3424.
63. Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27: 4371-4377.
64. Furman RR, Forero-Torres A, Shustov A, et al. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010; 51:228-235.
65. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets. 2008;8(2):156-171.
66. Woodworth J, Leigh BR, O'Brien S, et al. Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2004;104:4831.
67. Byrd JC, Castro J, O'Brien S, et al. Comparison of results from a phase 1/2 study of lumiliximab (Anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. ASH Annual Meeting Abstracts. 2006;108:32.
68. Byrd JC, O'Brien S, Flinn I, et al. Safety and efficacy results from a phase I trial of single-agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2004; 104:2503.
69. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010;115:489-495.
70. LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998;91:399-405.
71. Frankel AE, Fleming DR, Powell BL, et al. DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opin Biol Ther. 2003;3:179-186.
72. Morgan SJ, Seymour JF, Prince HM, et al. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res. 2004;10:3572-3575.
73. Gonzalvez F AA: New insights into apoptosis signaling by Apo2L/ TRAIL. Oncogene. 2010;29:4752-65.
74. Inoue S, MacFarlane M, Harper N, et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 2004 (11 Suppl 2):S193-S206.
75. Plumas J, Jacob MC, Chaperot L, et al. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 1998;91:2875-2885.
76. MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002;21:6809-6818.
77. Czuczman MS, Maddipatla S, Knight J, et al. In vitro synergistic antitumor activity by targeting TRAIL-R1 and CD20 antigen by combining HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) and rituximab monoclonal antibody against non-Hodgkin's lymphoma cells (NHL). ASH Annual Meeting Abstracts. 2005;106:1475.
78. Ghoshal P, Chitta K, Vujcic S, et al. Mapatumumab, a TRAIL receptor 1 agonist antibody, induces apoptosis in bortezomib resistant multiple myeloma. ASH Annual Meeting Abstracts. 2009;114:2832.
79. Younes A, Vose JM, Zelenetz AD, et al. Results of a phase 2 Trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts. 2005;106:489.
80. Natoni A, MacFarlane M, Inoue S, et al. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol. 2007;139:568-577.
81. Marks PA, Richon VM, Kelly WK, et al. Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp. 2004;259: 269-281; discussion 281-288.
82. Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia. 2005;19:2195-21202.
83. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495-528.
84. Herishanu Y P-GP, Liu D et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117: 563-574.
85. Friedberg JW SJ, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578-2585.
86. H genes. Blood. 2008;112:1443-1452.
87. Amrein PC, Attar E, Takvorian T, et al. Dasatinib has activity in relapsed/refractory chronic lymphocytic leukemia (CLL/SLL), a phase II trial. ASH Annual Meeting Abstracts. 2008;112:3162.
88. Wang S, Yang D, Lippman ME: Targeting Bcl-2 and Bcl-XL with non peptidic small-molecule antagonists. Semin Oncol. 2003;30:133-142.
89. Letai A, Sorcinelli MD, Beard C, et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 2004;6:241-249.
90. Patel MP MA, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol. 2009;21:516-523.
91. O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol. 2009;27:5208-5212.
92. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 2007;104: 19512-19517.
93. Borthakur G, O'Brien S, Ravandi-Kashani F, et al. A phase I trial of the small molecule pan-Bcl-2 family inhibitor obatoclax mesylate (GX15-070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2006;108:2654.
94. Balakrishnan K, Burger JA, Wierda WG, et al. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009;113:149-153.
95. James D, Castro JE, Loria O, Prada CE, Aguillon RA, Kipps TJ. AT-101, a small molecule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trial. J Clin Oncol. 2006;24:6605.
96. Castro JE, Olivier LJ, Robier AA, et al. A Phase II, Open Label Study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2006;108:2838.
97. Stolz C, Hess G, Hahnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood. 2008;112:3312-3321.
98. Wilson W, O'Conner O, Roberts AW, et al. ABT-263 activity in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). J Clin Oncol. 2009;27:15s.
99. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3 K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18:1391-1400.
100. De Frias M, Iglesias-Serret D, Cosialls AM, et al. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2009; 94(12):1698-1707.
101. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078-2088.
102. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2010;116:55.
103. O'Brien S. New agents in the treatment of CLL. Hematology Am Soc Hematol Educ Program. 2008:457-464.
104. Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537-549.
105. Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta. 2011;1816(2):89-104. Epub ahead of print.
106. Jones DT, Addison E, North JM, et al. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. Blood. 2004; 103:1855-1861.
107. Lin K, Rockliffe N, Johnson GG, et al. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene. 2008;27:2445-2455.
108. Chen R, Keating MJ, Gandhi V, et al. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005;106:2513-2519.
109. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399-404.
110. Lanasa MC, Andritsos L, Brown JR, et al. Interim analysis of EFC6663, a multicenter phase 2 study of alvocidib (flavopiridol), demonstrates clinical responses among patients with fludarabine refractory CLL. ASH Annual Meeting Abstracts. 2010;116:58.
111. Tong WG, Chen R, Plunkett W, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010;28(18):3015-3022.
112. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378-4384.
113. Knauf WU, Lissichkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. ASH Annual Meeting Abstracts. 2007;110:2043.
114. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts. 2009;114:205.